Abstract: Provided is a method for treating a disease in which Hic-5 participates. A composition comprising a Hic-5 inhibitor, said composition being for treating a disease selected from among cardiomegaly, interstitial pneumonia, osteoarthritis, fatty liver and tumor, or for inhibiting vascular invasion of cancer cells.

Abstract: A drug for renal disease, the drug including a compound represented by the following Formula (I) as an active ingredient.

Abstract: A detection method of detecting CTCs as target cells contained in a test sample, the method includes a concentration step of concentrating the target cells contained in the test sample, a labeling step of labeling the target cells and other components by bringing the concentrated test sample into contact with first labeling antibodies in which antibodies specifically binding to antigens, which exclude antigens expressing in epithelial cells and specifically express in the target cells, are labeled by a first labeling substance, and into contact with second labeling antibodies in which antibodies binding to antigens expressing in the other components excluding the target cells are labeled by a second labeling substance, and a detection step of detecting, from the test sample, cells that are labeled by the first labeling antibodies and are not labeled by the second labeling antibodies as the target cells.

Abstract: The present invention provides a compound having a dihydropyran structure, a method of producing a compound having a dihydropyran structure, a method of producing Pre-SMTP, a method of producing a group of SMTPs, and a pharmaceutical composition. The compound having a dihydropyran structure can be a useful intermediate in the chemically producing a group of Pre-SMTP and SMTP. Specifically, the compound having a dihydropyran structure is represented by formula (1), wherein: R3Si is a silyl group selected from TMS: trimethylsilyl, TES: triethysilyl, TBS (TBDMS): tert-butyldimethylsil, TIPS: triisopropylsilyl, TBDPS: tert-butyldiphenylsilyl, X is selected from COOH, CHO, and —CH?C(HCH3)—(CH2)2—CH?C(CH3)2.

Abstract: Disclosed is a cytoprotective agent for use with respect to ischemic damage, including as an active ingredient a triprenyl phenol compound represented by the following general formula (I), wherein X is —CHY—C(CH3)2Z, Y and Z are each independently —H or —OH, or jointly form a single bond, and R represents a hydrogen atom or a substituent with a molecular weight of 1000 or less.

Abstract: It is possible to provide a small intestine endoscope training simulator (11) which allows to obtain a feeling similar to that of inserting an endoscope (38) into the small intestine (34) of the living body (30) and learn the actual operation of the endoscope (38). This training simulator (11) includes a plurality of longitudinal elastic members (32) for applying an elastic force to each of a plurality of portions of a simulated small intestine (13). One end portion sides of the plurality of longitudinal elastic members (32) are respectively attached to the first attachment portions (27) on the simulated small intestine (13) side. The other end portion sides of the plurality of longitudinal elastic members (32) are respectively attached to the second attachment portions (33, 57) on the case (12) side.

Abstract: The object aims to form and maintain a cell, a tissue or an organ induced by differentiation. Disclosed is a composition for inducing the differentiation of a cell capable of being differentiated in a given direction to thereby produce a cell, a tissue or an organ through the further induction of the differentiation in the given direction. The composition comprises NELL-1 or a substance which can be altered so as to act as NELL-1 upon the differentiation. Also disclosed is a composition for maintaining a cell, a tissue or an organ produced by the induction of the differentiation.

Abstract: A rod-shaped device holds the equatorial region of the lens capsule during cataract/intraocular lens implantation surgery of patients with a weak or ruptured Zinn zonule. The device has a handle with a length of 6 mm or more and a thickness ranging from 0.01 mm to 1.0 mm, a tip bent into an acute angle, with the length up to this angled tip being 1.5 mm or more from the trough of the bend, and the bent tip having a linear branched or flat pad, with the width between the branches being 1 mm or more or the flat pad having a surface area of 1 mm2 or more.

Abstract: Disclosed are: a compound which can be produced through a chemical synthesis at low cost, has an excellent osteogenesis-promoting activity, has high affinity for a bone, and can be applied without the need of any special DDS; and a method for promoting osteogenesis by administering the compound and applying the promotion of osteogenesis to the formation or regeneration of a bone. Specifically disclosed are: an osteogenesis promoter or a pharmaceutical composition comprising [4-(methylthio)phenylthio]methanebisphosphonic acid, which is one of bisphosphonic acids, or a pharmaceutically acceptable salt thereof as an active ingredient; and a method for promoting osteogenesis, which comprises administering the osteogenesis promoter or the pharmaceutical composition to a subject to be treated.

Abstract: An endoscopic inspection method includes staining step and super magnified observation step. In the staining step, a distal end surface of a distal end portion of an endoscope which includes a distal end opening of a channel and a first lens that forms a super high-power observation optical system is held in contact with the tissue surface of the observation subject region such that the staining fluid supplied via the channel penetrates to the gap between the distal end surface and the tissue surface to eliminate the mucus on the tissue surface. The tissue surface having the mucus eliminated is stained with the staining fluid. In the super magnified observation step, the first lens which forms the super high-power observation optical system provided at the distal end portion is brought into contact with the tissue surface that has been stained with the staining fluid such that the observation at the cellular level is performed.

Abstract: A method is disclosed for cryopreserving living animal cells in immunoisolation membranes, including: (1) cutting out a living organ from an animal, (2) digesting the cutout organ into the discrete living animal cells and separating the discrete cells, (3) suspending the separated cells in a solution of sodium chloride containing sodium alginate and collagen, (4) forming microcapsules of the living animal cells by using the resulting suspension, (5) forming immunoisolation membranes around outer surfaces of the microcapsules of the living animal cells by covering the outer surfaces with alginate-(poly-L-lysine) and thereby obtaining the living animal cells enclosed in the immunoisolation membranes, (6) suspending the resulting living animal cells enclosed in the immunocapsules in a cell damage-preventing solution, and (7) immediately freezing the thus obtained suspension with liquid nitrogen.

Abstract: An endoscopic inspection method includes staining step and super magnified observation step. In the staining step, a distal end surface of a distal end portion of an endoscope which includes a distal end opening of a channel and a first lens that forms a super high-power observation optical system is held in contact with the tissue surface of the observation subject region such that the staining fluid supplied via the channel penetrates to the gap between the distal end surface and the tissue surface to eliminate the mucus on the tissue surface. The tissue surface having the mucus eliminated is stained with the staining fluid. In the super magnified observation step, the first lens which forms the super high-power observation optical system provided at the distal end portion is brought into contact with the tissue surface that has been stained with the staining fluid such that the observation at the cellular level is performed.